Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...

On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...

Mer­ck said its “once-in-a-life­time” drug Keytru­da could be sub­ject to price re­duc­tions un­der the In­fla­tion Re­duc­tion Act, which would lead to a … ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication developed by Merck that has raked in more than $130 billion in sales for the ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

تحولی در برند، تعهدی به آینده همراه اول، با تکیه بر سابقه ای درخشان در صنعت ارتباطات و الهام از نیازهای متنوع جامعه، گام در مسیری تازه نهاده ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...

رقابت؛ نیروی محرک توسعه صنعت داروسازیو جود برند ژنریک، محرکی برای رقابت سالم در بازار دارویی است. تولیدکنندگان برای بهبود کیفیت، ارائه فناو ...